NSE: ROSSARI | BSE: 543213

Slowing Down Stock

Download real time

682.35 3.60 (0.53%)

29.85% Fall from 52W High

31,336 NSE+BSE Volume

NSE 27 Jun, 2025 3:31 PM (IST)

3,777.9

Market Cap

Above industry Median

0.7

Beta 1Year

Very Low volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Rossari Biotech Ltd.

25 Jan 2024

682.35

0.53%

Strong revenue growth with stable profitability

Buy: Rossari Biotech Ltd.

Recommendation Target

KRChoksey

For Q3FY24, Rossari Biotech's revenue was INR 4,638 Mn which grew by 19.1% YoY but declined by 4.1% QoQ. This growth was driven by strong growth in HPPC segment, which posted solid double-digit growth of 31.1% YoY but declined 3.2% QoQ to reach revenue of INR 3,554 Mn.

Rossari Biotech Ltd. is trading below its 150 day SMA of 709.0

Rossari Biotech Ltd.

24 Jan 2024

682.35

0.53%

Rossari Biotech | Q3FY24 Result Update

Buy: Rossari Biotech Ltd.

Edelweiss

HPPC business and capex to drive growth

Rossari Biotech Ltd. is trading below its 150 day SMA of 709.0

Rossari Biotech Ltd.

27 Oct 2023, 12:00AM

682.35

0.53%

Margins remain under pressure due to price correction

Accumulate: Rossari Biotech Ltd.

Recommendation Target

KRChoksey

The HPPC segment posted solid double-digit growth (20.8% YoY and 21.9% QOQ) in revenue to reach INR 3,671 Mn. The strong performance in the company’s core segment was led by healthy contributions from Institutional cleaning, Paints, and Home and Personal care. The revenue contribution grew to 75.9% of the total revenue in Q2FY24 compared to 71.4% in Q2FY23.

Rossari Biotech Ltd. is trading above its 100 day SMA of 664.4

Rossari Biotech Ltd.

24 Oct 2023

682.35

0.53%

Rossari Biotech | Q2FY24 Result Update

Buy: Rossari Biotech Ltd.

Edelweiss

Signs of a recovery in sight

Rossari Biotech Ltd. is trading below its 150 day SMA of 709.0

Rossari Biotech Ltd.

24 Oct 2023

682.35

0.53%

Volume jumps at the cost of margins

Sell: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q2FY24 HPPC revenue (+21% YoY) was led by a volume push which has hurt prices and margins. Despite rise in utilisation from 50-55% to >75%, EBITDA margin dipped 100bp QoQ to 13.1%. It has chosen to play volume game for FY24 to drive utilisation, and expects to improve margins as plant utilisations stabilise at higher levels, which in our view can cap return ratio in near term.

Rossari Biotech Ltd. is trading above its 100 day SMA of 664.4

Rossari Biotech Ltd.

01 Aug 2023

682.35

0.53%

Performance acceleration may take some time

Sell: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari Biotech’s (Rossari) Q1FY24 revenue dipped 5.5% YoY to Rs4.1bn due to drop in raw material prices, while volume grew ~20% YoY. Gross profit margin dipped 10bps QoQ despite softening raw material prices as the company focused on growing volumes and driving operating leverage. EBITDA margin has improved 70bps QoQ to 14.1%. Rossari expects revenue growth of 12-14% and EBITDA margin at 14% for FY24 despite a weak Q1FY24.

Rossari Biotech Ltd. is trading above its 100 day SMA of 664.4

Rossari Biotech Ltd.

01 Aug 2023

682.35

0.53%

Robust product launch pipeline will drive future growth

Buy: Rossari Biotech Ltd.

Target

KRChoksey

The HPPC segment witnessed a growth of 7% on QoQ and a de-growth of 11% YoY basis and contributed 68.9% to the total revenue, the revenues from this segment stood at INR 2,829 Mn. During the quarter, the HPPC segment showed a stable performance, even with weak demand in key domestic industries.

Rossari Biotech Ltd. has an average target of 924.25 from 4 brokers.

Rossari Biotech Ltd.

03 May 2023

682.35

0.53%

Rossari Biotech | Q4FY23 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

Signs of a recovery in sight

Rossari Biotech Ltd. is trading below its 150 day SMA of 709.0

Rossari Biotech Ltd.

03 May 2023

682.35

0.53%

Unexciting performance

Hold: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s Q4FY23 revenue dipped 7.4% YoY (rose 4.4% QoQ) to Rs4.1bn due to drop in raw material prices. However, we were disappointed by a 40bps QoQ contraction in gross profit margin to 29.6%. EBITDA growth therefore was just 4.3% YoY.

Rossari Biotech Ltd. is trading above its 100 day SMA of 664.4

Rossari Biotech Ltd.

10 Feb 2023

682.35

0.53%

Margin improved despite challenges in revenue growth

Buy: Rossari Biotech Ltd.

Target

KRChoksey

The consolidated revenue of Rossari declined by 9.1% YoY/8.5% QoQ to INR 3893mn due to subdued revenue performance in the subsidiaries that led to lower sales in (HPPC) segment for the current quarter. Ongoing challenges in export markets such as Europe and Russia had a substantial impact on Tristar, while Unitop faced headwinds in the agrochemical business.

Rossari Biotech Ltd. has an average target of 924.25 from 4 brokers.

VOTE: Is Rossari Biotech Ltd. worth buying?

67 Votes:

Buy 91.04%

Sell 2.99%

Hold 5.97%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf